Valganciclovir HCl is primarily used in the treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as those who have undergone organ transplants. It is effective in preventing CMV disease in kidney, heart, and kidney-pancreas transplant recipients. Additionally, it is used to treat CMV retinitis in patients with AIDS. The medication works by inhibiting the replication of the virus, thereby controlling the infection and reducing the risk of complications. It is often preferred due to its oral bioavailability, which allows for convenient administration compared to intravenous alternatives.